Innovative Collaboration between datma and Rhythm Biosciences to Enhance Genomic Diagnostics

Beaverton, Ore. and Parkville, Australia — December 22, 2025
In an exciting development for the realm of predictive diagnostics, datma, a pioneer in federated real-world data access, has announced a collaborative partnership with Rhythm Biosciences Ltd (ASX: RHY), an innovative player in the field of cancer diagnostics. This collaboration seeks to explore the capabilities of datma’s federated data platform in supporting the advancement of Rhythm Biosciences' genomic-integrated risk prediction technologies.

As genomic medicine continues to evolve, the demand for high-quality real-world data to improve model performance and widen the clinical implications becomes increasingly essential. Yet, access to such crucial datasets is often hampered by fragmentation and privacy constraints. datma.FED, the powerful federated data platform launched by datma, aims to address these issues by permitting secure, federated access to de-identified data among participating healthcare organizations, without requiring the centralized movement of sensitive information.

The partnership initiates a comprehensive evaluation of how long-term, de-identified clinical data accessible through datma.FED can aid in refining Rhythm’s genomic-integrated risk scoring technologies, particularly their leading solution, geneType™. Rhythm seeks to utilize these datasets to enhance evidence generation about clinical utility and to develop health economic models that will facilitate discussions with healthcare systems regarding the adoption of sophisticated population-based risk stratification tools.

In a statement regarding the collaboration, Noah Nasser, CEO of datma, expressed enthusiasm about the initiative. He stated, “We are excited to collaborate with Rhythm Biosciences as they continue advancing genomic-integrated risk prediction to support cancer diagnostics. datma.FED was built to enable secure access to high-value data across institutions, and this collaboration reflects the growing demand for federated access to data that can support development and research efforts, whether in diagnostics, therapeutics, or real-world evidence generation.”

Complementarily, Dr. Erika Spaeth, Director of Clinical Affairs at Rhythm Biosciences, emphasized the critical nature of data access in proving the clinical relevance of genomic-integrated risk prediction tools. She articulated, “This collaboration allows us to explore how federated data access can support evidence generation for geneType™ as we continue to advance our portfolio and engage with healthcare systems on future implementation pathways.”

Rhythm Biosciences has its sights set on developing scalable, population-based solutions aimed at bolstering cancer risk predictions and enhancing early detection capabilities. Their geneType™ risk prediction tool is designed to foster affordable, personalized screening within healthcare systems, ultimately aiding in increasing screening compliance while optimizing resource allocation.

The current stage of collaboration will include the cross-validation of geneType™ utilizing federated real-world datasets, a pivotal step toward enhancing clinical utility and facilitating significant interactions with healthcare systems regarding population-stratified screening models. Conditional on successful validation, the partners will further discuss collaboration opportunities, potentially integrating geneType™ technology into the datma.FED ecosystem.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX RHY) operates out of Melbourne, Australia, with a mission to create simple, accessible blood tests for the early and accurate detection of cancers. The organization is committed to enhancing patient outcomes by focusing on early detection, aiming to reduce the global cancer burden and save lives. Established in 2017, Rhythm is determined to partner with like-minded global entities for commercialization and distribution purposes. For more details, visit rhythmbio.com and follow them on LinkedIn and X.

About datma

datma leverages a secure, federated ecosystem to transform healthcare data access and sharing, fostering collaborative relationships between data custodians and consumers. Headquartered in Beaverton, Oregon, datma has developed the datma.FED platform, a marketplace for real-world healthcare data that supports compliant collaboration while maintaining data privacy. Equipped with advanced data storage capabilities and AI-enhanced tools for harmonizing diverse datasets, datma.FED prioritizes maximum data utility while ensuring minimal technical hurdles for participating organizations. To learn more about datma, visit www.datma.com.